Risk Factors for New-Onset Diabetes Mellitus in Patients Receiving Protease Inhibitor Therapy
BACKGROUND: Metabolic complications including diabetes mellitus (DM) have been associated with protease inhibitor (PI) therapy. Risk factors for the development of DM are not well-defined.
Main Authors: | Christine A Hughes, Richard P Cashin, Dean T Eurich, Stan Houston |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2005-01-01
|
Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
Online Access: | http://dx.doi.org/10.1155/2005/971971 |
Similar Items
-
Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
by: Constantine E Kosmas, et al.
Published: (2018-11-01) -
Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors
by: Jeerunda Santiprabhob, et al.
Published: (2017-01-01) -
The Impact of Diabetes Mellitus on Cardiovascular Risk Onset in Children and Adolescents
by: Ida Pastore, et al.
Published: (2020-07-01) -
Proteases and Protease Inhibitors of Urinary Extracellular Vesicles in Diabetic Nephropathy
by: Luca Musante, et al.
Published: (2015-01-01) -
The aetiology of juvenile-onset diabetes mellitus
by: Lillington, A. W.
Published: (1979)